Hin Sang Group (International) Holding Co. Ltd.

Hin Sang Group (International) Holding Co. Ltd.

6893.HK
Hin Sang Group (International) Holding Co. Ltd.HK flagHong Kong Stock Exchange
0.17
HKD
+0.00
- -
186.70MMarket Cap
Hin Sang Group (International) Holding Co. Ltd.
6893.HK
(Hong Kong Stock Exchange)

Recent

price

0.17

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.42
0.31
0.28
0.2
0.17
0.17
0.16
0.11
0.11
0.07
0.08
0.08
Revenue per Share
0.08
0.02
0.03
0.01
- -
- -
-0.02
-0.03
-0.01
-0.05
-0.03
-0.05
Basic EPS, GAAP
0.04
- -
-0.01
-0.06
-0.04
-0.21
-0.13
-0.05
0.02
- -
0.01
- -
Free Cash Flow per Basic Share
- -
0.04
0.02
0.03
0.02
0.02
- -
- -
- -
- -
- -
- -
Dividend per Share
0.21
0.27
0.24
0.19
0.16
0.16
0.14
0.1
0.1
0.06
0.02
-0.02
Book Value per Share
0.16
0.48
0.43
0.85
0.9
0.46
0.31
0.29
0.28
0.22
0.19
0.14
Tangible Book Value per Share
600
692
800
1,021
1,091
1,094
1,093
1,092
1,092
1,092
1,092
1,092
Basic Weighted Avg Shares
253
215
227
202
189
184
176
119
121
81
93
92
Sales/Revenue/Turnover
23.34
6.18
11.26
7.21
3.31
0.86
2.13
-22.15
-9.04
-42.55
-22.36
-23.53
Operating Margin (%)
2
3
5
8
12
12
20
21
20
18
17
14
Depreciation Expense
50
11
21
10
1
5
-20
-32
-12
-49
-37
-49
Net Income, GAAP
18.75
28.47
21.37
36.17
780.58
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
19.63
5.14
9.33
4.85
0.28
2.54
-11.23
-26.75
-9.88
-60.75
-39.63
-53.72
Profit Margin (%)
52
286
263
305
220
-48
-35
-103
-126
-174
-199
-221
Working Capital
- -
- -
- -
- -
- -
- -
191
227
201
162
134
132
LT Debt
94
335
346
871
984
507
337
320
302
240
209
156
Total Equity
- -
4.37
5.9
1.53
-4.56
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
7.12
11.16
5.28
3.63
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
7.12
11.26
5.04
0.28
2.66
-12
-24.2
-10.81
-57.57
-86.69
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.64%
-13.89%
-25.42%
Free Cash Flow
-241.06%
-149.67%
-176.03%
Net Income, GAAP
52.33%
64.58%
34.48%
Sales/Revenue/Turnover
-6.95%
-10.16%
-0.79%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
93
2025
- -
- -
- -
- -
92
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.03
2025
- -
- -
- -
- -
-0.05
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Hin Sang Group (International) Holding Co. Ltd. engages in the manufacture, marketing, and sale of healthcare products primarily targeting children in Hong Kong and Mainland China. The company operates through four key segments: Product Development, Brand Development and Management, Trading of Goods, and Healthcare. Its Product Development segment develops and sells personal care products, household products, and health supplements under brands including Hin Sang, Tai Wo Tong, Cheers Smart, Care Plus, Shuang Long, and King's Antiseptic. The Brand Development and Management segment handles marketing, sales, distribution, logistics, and delivery for personal care products under brands such as Pahmi, Enear, Vcnic, Zici, and Sunew, while also managing brands for proprietors. The Trading of Goods segment trades and distributes skincare, personal care, and household products sourced from authorized dealers, independent traders, manufacturers, and parallel importers. The Healthcare segment provides Chinese medical healthcare services including treatment and consultation for mothers and children, and develops mother- and child-related health products and medical centers. Founded in 1996, the company is headquartered in Tsim Sha Tsui, Hong Kong and operates across Mainland China, Hong Kong, Macau, Taiwan, and Southeast Asia. It is a subsidiary of Genwealth Group Holding Company Limited. Recent major changes include the company's strategic focus on expanding its presence in the Mainland China market, especially in children's health supplements, leveraging China's three-child policy. Hin Sang Group continues to develop and launch new products under its own brands Hin Sang, Weverse, and Yabune, which combine traditional herbal ingredients with advanced technology, and holds certifications such as HKC and GMP. The group has invested in its Hin Sang Health Medical Industrial Park in Yunfu City, Guangdong Province, enhancing production capacity with fully automated production lines for beverages, convenience foods, and confectionery products, as well as OEM and ODM manufacturing services. It is also upgrading its e-commerce platform to expand online sales, particularly targeting Mainland China customers. Cost containment measures and administrative expense reductions have improved the group's financial performance in recent periods. The company plans to strengthen brand recognition, expand its distribution network by recruiting more distributors, and focus on marketing to respond to changing consumer behavior while maintaining a strong position in the Hong Kong health supplement market. Hin Sang Group maintains a comprehensive product portfolio of health supplements, traditional Chinese medicines, personal care, and household products marketed under multiple proprietary and distributed brands. It also actively engages in Chinese medicine cultural education and eco-industrial development as part of its broader healthcare business strategy. This description reflects Hin Sang Group's diverse operations and recent strategic developments up to 2025.